This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
10: External Data Submission Timing The NHC understands the tight timeline for the drug selection and price negotiation processes. The NHC believes that CMS may need to reevaluate methodology for various pieces of the negotiation process, including aggregating drugs to determine MFP. Sincerely, Randall L.
GlobalData predicts that Comirnaty’s sales will increase by more than 20% between 2024 and 2027. Using nanomedicine to overcome drug delivery barriers Apart from lipid nanoparticles, nanoparticle-related innovation is also reaching other types of drugdevelopment. Please check your email to download the Report.
Life sciences venture capital firm Flagship Pioneering has unveiled Empress Therapeutics, a small molecule drugdevelopment startup. This will support development of its proprietary Chemilogics platform and drug discovery pipeline. So far, Empress claims to have generated 15 drug leads across multiple indications.
Over the past few years, there has been a boom in anti-obesity drugdevelopment, with major companies achieving substantial sales in the field. According to GlobalData, as of November 28, there were 316 generic and novel drugs marketed to treat obesity. Anti-obesity therapeutic landscape.
Over the past few years, there has been a boom in anti-obesity drugdevelopment, with major companies achieving substantial sales in the field. According to GlobalData, as of November 28, there were 316 generic and novel drugs marketed to treat obesity. Anti-obesity therapeutic landscape.
The biopharmaceutical industry is witnessing unprecedented growth, with the Contract Development and Manufacturing Organization (CDMO) market expected to reach $289.64 billion by 2027. This involves defining clear goals, outlining project deliverables, and establishing effective communication channels. 2022, November 7).
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content